Tropical Medicine and Infectious Disease (Oct 2021)

Pregnancy, Birth, Infant, and Early Childhood Neurodevelopmental Outcomes among a Cohort of Women with Symptoms of Zika Virus Disease during Pregnancy in Three Surveillance Sites, Project <i>Vigilancia de Embarazadas con Zika</i> (VEZ), Colombia, 2016–2018

  • Marcela Mercado-Reyes,
  • Suzanne M. Gilboa,
  • Diana Valencia,
  • Marcela Daza,
  • Van T. Tong,
  • Romeo R. Galang,
  • Christina M. Winfield,
  • Shana Godfred-Cato,
  • Mónica Benavides,
  • Julie M. Villanueva,
  • Jennifer D. Thomas,
  • Jonathan Daniels,
  • Sherif Zaki,
  • Sarah Reagan-Steiner,
  • Julu Bhatnagar,
  • Jarad Schiffer,
  • Evelene Steward-Clark,
  • Jessica N. Ricaldi,
  • Johana Osorio,
  • Christina L. Sancken,
  • Lissethe Pardo,
  • Sarah C. Tinker,
  • Kayla N. Anderson,
  • Angelica Rico,
  • Veronica K. Burkel,
  • Jacob Hojnacki,
  • Miranda J. Delahoy,
  • Maritza González,
  • May B. Osorio,
  • Cynthia A. Moore,
  • Margaret A. Honein,
  • Martha Lucia Ospina Martinez

DOI
https://doi.org/10.3390/tropicalmed6040183
Journal volume & issue
Vol. 6, no. 4
p. 183

Abstract

Read online

Project Vigilancia de Embarazadas con Zika (VEZ), an intensified surveillance of pregnant women with symptoms of the Zika virus disease (ZVD) in Colombia, aimed to evaluate the relationship between symptoms of ZVD during pregnancy and adverse pregnancy, birth, and infant outcomes and early childhood neurodevelopmental outcomes. During May–November 2016, pregnant women in three Colombian cities who were reported with symptoms of ZVD to the national surveillance system, or with symptoms of ZVD visiting participating clinics, were enrolled in Project VEZ. Data from maternal and pediatric (up to two years of age) medical records were abstracted. Available maternal specimens were tested for the presence of the Zika virus ribonucleic acid and/or anti-Zika virus immunoglobulin antibodies. Of 1213 enrolled pregnant women with symptoms of ZVD, 1180 had a known pregnancy outcome. Results of the Zika virus laboratory testing were available for 569 (48.2%) pregnancies with a known pregnancy outcome though testing timing varied and was often distal to the timing of symptoms; 254 (21.5% of the whole cohort; 44.6% of those with testing results) were confirmed or presumptive positive for the Zika virus infection. Of pregnancies with a known outcome, 50 (4.2%) fetuses/infants had Zika-associated brain or eye defects, which included microcephaly at birth. Early childhood adverse neurodevelopmental outcomes were more common among those with Zika-associated birth defects than among those without and more common among those with laboratory evidence of a Zika virus infection compared with the full cohort. The proportion of fetuses/infants with any Zika-associated brain or eye defect was consistent with the proportion seen in other studies. Enhancements to Colombia’s existing national surveillance enabled the assessment of adverse outcomes associated with ZVD in pregnancy.

Keywords